This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Non Invasive Measurement of Cardiac Index by Impedance Cardiography

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Medical University of Graz
ClinicalTrials.gov Identifier:
NCT01607515
First received: April 13, 2012
Last updated: September 7, 2015
Last verified: September 2015
April 13, 2012
September 7, 2015
March 2012
June 2015   (Final data collection date for primary outcome measure)
Comparison of CI measured by ICG and Thermodilution [ Time Frame: recruitment over 1.5 year (Data collection), followed by data analysis and interpretation (overall 2 yearsfrom start of recruitment) ]
assessment of the Specificity and sensitivity of ICG for CI measurement
Comparison of CI measured by thermodilution (RHC) and ICG [ Time Frame: 1.5 years ]
Complete list of historical versions of study NCT01607515 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Non Invasive Measurement of Cardiac Index by Impedance Cardiography
Non Invasive Measurement of Cardiac Index by Impedance Cardiography

Pulmonary hypertension (PH) is defined as a pulmonary arterial mean pressure (meanPAP) ≥ 25 mmHg in the right heart catheterization.

There are different forms of PH defined in the classification of Dana Point 2008.

PH is diagnosed with right heart catheterization but there are other non invasive methods which can be used for screening like echocardiography, stress echocardiography and cardio pulmonary exercise testing.

For prognosis of PH patients the limitation of the pulmonary circulation is very important. Therefore the cardiac index (CI) is a good parameter for the right ventricular function. The gold standard for CI measures is the thermodilution, an invasive method performed during right heart catheterization.

In this study the investigators want to evaluate the impedance cardiography (ICG) as a non invasive method for CI measurement. An alternating current of max 400µA and 45 kHz is conducted through the body. The way of the smallest resistance is the blood in the aorta. The impedance changes with the pulsatile blood flow. Out of the Impedance change there can be calculated the CI.
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Pulmonary Hypertension
Other: Impedance cardiography
noninvasive measure of cardiac index by impedance cardiography.
Other Name: patients with a clinical suspicion of PH
suspected PH
Patients who undergo right heart catheterization for PH diagnosis undergo impedance cardiography
Intervention: Other: Impedance cardiography
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
89
June 2015
June 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients who have right heart catheterization written informed consent

Exclusion Criteria:

  • patients who don't have right heart catheterization no written informed consent
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Austria
 
 
NCT01607515
24-205 ex 11/12
No
Not Provided
Not Provided
Medical University of Graz
Medical University of Graz
Not Provided
Principal Investigator: Horst Olschewski, MD Medical University of Graz
Medical University of Graz
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP